Found 294 clinical trials
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US
(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system
- 1875 views
- 26 Mar, 2021
- 15 locations
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish
(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system
- 268 views
- 26 Mar, 2021
- 16 locations
A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- 180 views
- 25 Mar, 2021
- 1 location
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- 45 views
- 14 Dec, 2020
- 5 locations
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis
large B-cell lymphoma (DLBCL).
- 32 views
- 23 Jan, 2021
- 18 locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.
- 0 views
- 13 Jun, 2021
- 24 locations
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving
- 0 views
- 09 Apr, 2021
- 2 locations
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
with relapsed or refractory chemosensitive diffuse large B-cell lymphoma
- 28 views
- 07 Nov, 2020
- 1 location
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma
This is an open-label, multicenter, dose-escalation phase 1 study to determine the Safety and Efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.
- 0 views
- 23 Jan, 2021
- 2 locations
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.
- 0 views
- 27 Jan, 2021
- 1 location